ArticleMediators of inflammation2015
Neutrophilic Bronchial Inflammation Correlates with Clinical and Functional Findings in Patients with Noncystic Fibrosis Bronchiectasis.
Article in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- A systematic literature review of the clinical and socioeconomic burden of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Neutrophil elastase in bronchiectasis.Respiratory research · 2017Pooled it
- A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects.British journal of clinical pharmacology · 2025Trial
- Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers.Clinical and translational science · 2024Trial
- Age-Specific Considerations in Bronchiectasis Management: Focus on Older Adults with Emphasis on Anti-inflammatory Treatment.Drugs & aging · 2026Review
- Benralizumab in bronchiectasis: results from the phase 3 MAHALE study.ERJ open research · 2026Article
- Comparison of clinical and microbiological features between mucoid and non-mucoidMicrobiology spectrum · 2026Article
- The importance of symptoms in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- The Role of Alpha-1 Antitrypsin in the Pathophysiology and Treatment of Inflammatory Lung Diseases.Journal of inflammation research · 2026Review
- Diagnostic and prognostic value of miR-155 in non-cystic fibrosis bronchiectasis.BMC pulmonary medicine · 2025Article
- The cellular triangle in bronchiectasis: the interplay network and regulatory mechanisms of neutrophils, macrophages, and epithelial cells.European journal of medical research · 2025Review
- Inflammatory Phenotypes of Bronchiectasis.Journal of personalized medicine · 2025Review
- Pseudomonas aeruginosa infection exacerbates elastase induced lung damage: characterisation of a novel murine two-hit model of pulmonary infection.Respiratory research · 2025Article
- Bronchiectasis and sinonasal diseases: a narrative review.ERJ open research · 2025Review
- Dipeptidyl peptidase-1 inhibitors in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Neutrophilic inflammation in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration.British journal of clinical pharmacology · 2025Article
- Correlation of sputum inflammatory markers with severity and blood inflammatory markers in bronchiectasis.Journal of thoracic disease · 2024Article
- Biomarkers in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background. Neutrophilic bronchial inflammation is a main feature of bronchiectasis, but not much is known about its relationship with other disease features. Aim. To compare airway inflammatory markers with clinical and functional findings in subjects with stable noncystic fibrosis bronchiectasis (NCFB). Methods. 152 NFCB patients (62.6 years; females: 57.2%) underwent clinical and functional cross-sectional evaluation, including microbiologic and inflammatory cell profile in sputum, and exhaled breath condensate malondialdehyde (EBC-MDA). NFCB severity was assessed using BSI and FACED criteria. Results. Sputum neutrophil percentages inversely correlated with FEV1 (P < 0.0001; rho = -0.428), weakly with Leicester Cough Questionnaire score (P = 0.068; rho = -0.58), and directly with duration of the disease (P = 0.004; rho = 0.3) and BSI severity score (P = 0.005; rho = 0.37), but not with FACED. Sputum neutrophilia was higher in colonized subjects, P. aeruginosa colonized subjects showing greater sputum neutrophilia and lower FEV1. Patients with ≥3 exacerbations in the last year showed a significantly greater EBC-MDA than the remaining patients. Conclusions. Sputum neutrophilic inflammation and biomarkers of oxidative stress in EBC can be considered good biomarkers of disease severity in NCFB patients, as confirmed by pulmonary function, disease duration, bacterial colonization, BSI score, and exacerbation rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.